Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids

In Vivo

Volumn 25, Issue 6, 2011, Pages 1027-1029

  Manfè, Anna Zaira ^a   Norberto, Lorenzo ^a   Marchesini, Marco ^a   Lumachi, Franco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

5 HIAA; 5 hydroxyindolacetic acid; Carcinoids; CgA; Chromogranin A; Neuron specific enolase; NSE

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; TUMOR MARKER;

ADULT; AGE; AGED; APPENDIX; ARTICLE; BLOOD LEVEL; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOID; CLINICAL ARTICLE; FEMALE; HISTOLOGY; HUMAN; ILEUM; MALE; MEASUREMENT; NEUROENDOCRINE TUMOR; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYMPTOM; URINE LEVEL;

EID: 80755159140     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Warner RR: Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 128: 1668-1684, 2005.
2. Modlin IM, Lye KD and Kidd M: A 5-decade analysis of 13,751 carcinoid tumors. Cancer 97: 934-959, 2003. (Pubitemid 36173145)
3. Yao JC, Hassan M, Phan A, Daghoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans DB: One hundred years after 'carcinoid': epidemiology of and prognosis factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072, 2008.
4. Soga J: Gastric carcinoids: a statistical evaluation of 1094 cases collected from the literature. Surg Today 27: 892-901, 1997.
5. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P and Sundin A: Gastroenteropancreatic neuroendocrine tumors. Lancet Oncol 9: 61-72, 2008.
6. US National Cancer Institute: Surveillance Epidemiology and End Results (SEER) data base. 1973-2007.
7. Bashir S, Gibril F, Ojeaburn JV, Asgharian B, Entsuah LK, Ferraro G, Crafa P, Bordi C and Jensen RT: Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther 16: 1367-1382, 2002.
8. Lamberts R, Creutzfeldt W, Strüber HG, Brunner G and Solcia E: Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 104: 1356-1370, 1993. (Pubitemid 23235408)
9. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R, Thakker R, Aylwin S, Breen D, Britton K, Buchanan K, Corrie P, Gillams A, Lewington V, McCance D, Meeran K and Watkinson A: Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54: iv1-iv16, 2005. (Pubitemid 40695259)
10. Geode AC, Caplin ME and Winslet MC: Carcinoid tumour of the appendix. Br J Surg 90: 1317-1322, 2003. (Pubitemid 37421663)
11. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP and Conte D: Neuroendocrine tumors of the gastro-enteropancreatic system. World J Gastroenterol 21: 5377-5384, 2008.
12. Ramage JK, Goretzki PE, Manfredi R, Komminoth P, Ferone D, Hyrdel R, Kaltsas G, Kelestimur F, Kvols L, Scoazec JY, Garcia MI and Caplin: Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 87: 31-39, 2008.
13. Oberg KE: Gastrointestinal neuroendocrine tumors. Ann Oncol 21: vii72-vii80, 2010.
14. Bergenstuen DS, Aabakken L, Holm K, Vatn M and Thiis-Evensen E: Small intestine neuroendocrine tumors: prognostic factors and survival. Scan J Gastroenterol 44: 1084-1091, 2009.
15. Townsend A, Price T, Teed S, Pittman K, Patterson K and Luke C: Metastatic carcinoid tumor: changing patterns of care over two decades. J Clin Gastroenterol 44: 195-199, 2010.
16. Rindi G, D'Adda T, Froio E, Fellegra G and Bordi C: Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 18: 145-149, 2007. (Pubitemid 351378063)
17. Goebel SU, Serrano J, Yu F, Gibril F, Venzon DJ and Jensen RT: Prospective study of the value of serum chromogranin A or serum gastrin levels in assessment of the presence, extent, or growth of gastrinomas. Cancer 85: 1470-1483, 1999. (Pubitemid 29152818)
18. Børglum T, Rehfeld JF, Drivsholm LB and Hilsted L: Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas. Clin Chem 53: 438-446, 2007. (Pubitemid 46447940)
19. De Jong WH, Graham KS, de Vries EG and Kema IP: Urinary 5-HIAA measurement using automated on-line solid-phase extraction-high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 868: 28-33, 2008.
20. Nikou GC, Lygidakis NJ, Toubanakis C, Pavlatos S, Tseleni-Balafouta S, Giannatou E, Mallas E and Safioleas M: Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Hepatogastroenterology 52: 731-741, 2005.
21. Namwongprom S, Wong FC, Tateishi U, Kim EE and Boonyaprapa S: Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. Ann Nucl Med 22: 237-243, 2008. (Pubitemid 351809794)
22. de Herder WW: Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21: 33-41, 2007.
23. Eriksson B, Kloppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G and Wildi S: Consensus guidelines for the management of patients with digestive neuroendocrine tumors-well differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87: 8-19, 2008. (Pubitemid 350308290)
24. Modlin IM, Gustafsson BI, Pavel M, Svejda B, Lawrence B and Kidd M: A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival. Neuroendocrinology 92: 143-157, 2010.
25. Modlin IM, Moss SF, Oberg K, Padbury R, Hicks RJ, Gustafsson BI, Wright NA and Kidd M: Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aus 193: 46-52, 2010.
26. Oberg K and Stridsberg M: Chromogranin as diagnostic and prognostic markers in neuroendocrine tumours. Adv Exp Med Biol 482: 329-337, 2000. (Pubitemid 32174542)